New options for anticoagulation in congenital and pediatric acquired heart disease

Raffini, 2009, Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007, Pediatrics., 124, 1001, 10.1542/peds.2009-0768 Monagle, 2008, Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 133, 887S, 10.1378/chest.08-0762 Monagle, 2012, Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest, 141, e737S, 10.1378/chest.11-2308 Schulman, 2010, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients, J Thromb Haemost, 8, 202, 10.1111/j.1538-7836.2009.03678.x Dabbous, 2014, Anticoagulant therapy in pediatrics, J Basic Clin Pharm, 5, 27, 10.4103/0976-0105.134947 Young, 2015, Anticoagulants in children and adolescents, Hematology, 2015, 111, 10.1182/asheducation.V2015.1.111.3917444 Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903 Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507 Gibson, 2017, The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial, Am Heart J, 185, 93, 10.1016/j.ahj.2016.12.004 Eriksson, 2011, Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): a randomised, double-blind, non-inferiority trial, Thromb Haemost, 105, 721, 10.1160/TH10-10-0679 Franco Moreno, 2018, Direct oral anticoagulants: an update, Med Clín (Eng Ed), 151, 198, 10.1016/j.medcli.2017.11.042 Monagle, 2018, Management of thrombosis in children and neonates: practical use of anticoagulants in children, Hematol (United States), 2018, 399 Sutor, 1997, Heparin therapy in pediatric patients, Semin Thromb Hemost, 23, 303, 10.1055/s-2007-996103 Avila, 2013, Systematic review on heparin-induced thrombocytopenia in children: a call to action, J Thromb Haemost, 11, 660, 10.1111/jth.12153 Sutor, 2004, Low-molecular-weight heparin in pediatric patients, Semin Thromb Hemost, 30, 31, 10.1055/s-2004-823001 McCrindle, 2013, Factors associated with thrombotic complications after the Fontan procedure a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure, JAC, 61, 346 Ignjatovic, 2000, Dosing and monitoring of enoxaparin (low molecular weight heparin) therapy in children, Br J Haematol, 149, 734, 10.1111/j.1365-2141.2010.08163.x Bazinet, 2005, Dosage of enoxaparin among obese and renal impairment patients, Thromb Res, 116, 41, 10.1016/j.thromres.2004.10.004 Ahuja, 2018, Enoxaparin dosing and antixa monitoring in specialty populations: a case series of renal-impaired, extremes of body weight, pregnant, and pediatric patients, Pharm Ther, 43, 609 Van De Werf, 2012, A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN), Am Heart J, 163, 931, 10.1016/j.ahj.2012.03.011 Shazly, 2014, First trial of novel oral anticoagulant in patients with mechanical heart valves – the search continues, Glob Cardiol Sci Pract, 2014, 88 Goldstein, 2015, Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial, Lancet, 385, 2077, 10.1016/S0140-6736(14)61685-8 Rawal, 2019, Current status of oral anticoagulant reversal strategies: a review, Ann Transl Med, 7, 411, 10.21037/atm.2019.07.101 Willmann, 2018, Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase i study, Thromb J, 16, 1 Lensing, 2019, Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies, Artic Lancet Haematol, 6, 500, 10.1016/S2352-3026(19)30161-9 Lensing, 2018, Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study, Thromb J, 16, 1 Pina, 2019, Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post–Fontan procedure: rationale and design of a prospective, randomized trial (the UNIVERSE study), Am Heart J, 213, 97, 10.1016/j.ahj.2019.04.009 Dawwas, 2019, Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis, Lancet Haematol, 6, e20, 10.1016/S2352-3026(18)30191-1 Payne, 2019, A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study, Am Heart J, 217, 52, 10.1016/j.ahj.2019.08.002 Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Poulakos, 2017, Edoxaban: a direct oral anticoagulant, Am J Heal Pharm, 74, 117, 10.2146/ajhp150821 Ommen, 2020, The Edoxaban Hokusai VTE PEDIATRICS Study: an open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease, Res Pract Thromb Haemost, 4, 886, 10.1002/rth2.12352 VanderPluym, 2020, Utilization and outcomes of children treated with direct thrombin inhibitors on paracorporeal ventricular assist device support, ASAIO J, 66, 939, 10.1097/MAT.0000000000001093 Hamzah, 2020, Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation, Pediatr Crit Care Med, 21, 827, 10.1097/PCC.0000000000002384 Yeh, 2014, Evolving use of new oral anticoagulants for treatment of venous thromboembolism, Blood., 124, 1020, 10.1182/blood-2014-03-563056 Luciani, 2018, Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: rationale and design, Res Pract Thromb Haemost, 2, 580, 10.1002/rth2.12093 Halton, 2016, Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents: an open-label phase IIa study, Thromb Haemost, 116, 461 Halton, 2017, Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability, J Thromb Haemost, 15, 2147, 10.1111/jth.13847 Halton, 2017, Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism, Thromb Haemost, 117, 2168, 10.1160/TH17-06-0429 Yang, 2019, Antagonist oral anticoagulants in adults with a Fontan circulation: are they safe, Open Hear, 6 Khairy, 2013, Thrombosis in congenital heart disease, Expert Rev Cardiovasc Ther, 11, 1579, 10.1586/14779072.2013.854703 Yang H, Bouma BJ, Dimopoulos K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. https://doi.org/10.1016/j.ijcard.2019.06.014. Stalikas, 2020, Oral anticoagulants in adults with congenital heart disease: a systematic review, J Clin Med, 9, 1 Pujol, 2016, Usefulness of direct oral anticoagulants in adult congenital heart disease, Am J Cardiol, 117, 450, 10.1016/j.amjcard.2015.10.062 Monagle, 1998, Editorial: thromboembolic complications after Fontan procedures—the role of prophylactic anticoagulation, J Thorac Cardiovasc Surg, 115, 493, 10.1016/S0022-5223(98)70310-1 McCrindle, 2013, Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary Thromboprophylaxis for 2 years after the Fontan procedure, J Am Coll Cardiol, 61, 346, 10.1016/j.jacc.2012.08.1023 Viswanathan, 2016, Thromboembolism and anticoagulation after Fontan surgery, Ann Pediatr Cardiol, 9, 236, 10.4103/0974-2069.189109 Odegard, 2002, Coagulation abnormalities in patients with single-ventricle physiology precede the Fontan procedure, J Thorac Cardiovasc Surg, 123, 459, 10.1067/mtc.2002.120010 Odegard, 2009, Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion, J Thorac Cardiovasc Surg, 137, 934, 10.1016/j.jtcvs.2008.09.031 Odegard, 2003, Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis, J Thorac Cardiovasc Surg, 125, 1260, 10.1016/S0022-5223(02)73605-2 Jahangiri, 2000, Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation, J Thorac Cardiovasc Surg, 120, 778, 10.1067/mtc.2000.108903 Khairy, 2014, PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease, Can J Cardiol, 30, e1, 10.1016/j.cjca.2014.09.002 Stout, 2019, 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, Circulation, 139, e698 Baumgartner, 2020, 2020 ESC Guidelines for the management of adult congenital heart disease, Eur Heart J, 10.1093/eurheartj/ehaa701 Mongeon, 2019, Antagonist oral anticoagulants in adult congenital heart disease, Can J Cardiol, 35, 1686, 10.1016/j.cjca.2019.06.022 Chen, 2013, Thrombosis and embolism in pediatric cardiomyopathy, Blood Coagul Fibrinolysis, 24, 221, 10.1097/MBC.0b013e32835bfd85 McCrindle, 2017, Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association, Circulation., 135, e927, 10.1161/CIR.0000000000000484 Monagle, 2011, A multicenter, randomized trial comparing heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children, JAC., 58, 645 Manlhiot, 2012, Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation, J Pediatr, 161, 513, 10.1016/j.jpeds.2012.03.004